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BY-NC-ND license (http://creativecomAbstract Background/Purpose: To measure the inflammatory response in terms of tumor ne-
crosis factor-alpha (TNF-a) levels in cerebrospinal fluid (CSF), using bacteriolytic versus non-
bacteriolytic antibiotic therapy and adjunctive treatment with dexamethasone in an
experimental rabbit model of pneumococcal meningitis.
Methods: In a rabbit model of pneumococcal meningitis, we tested CSF TNF-a levels in several
samples from rabbits infected with the HUB 2349 strain and treated with ceftriaxone 100 mg/
kg/d, ceftriaxone plus vancomycin 30 mg/kg/d, or daptomycin at 15 mg/kg or 25 mg/kg. Dap-
tomycin schedules were compared with the same doses in combination with dexamethasone at
0.125 mg/kg every 12 hours over a 26-hour period.
Results: The ceftriaxone group had the highest levels of TNF-a. TNF-a levels were significantly
higher after ceftriaxone administration than in both daptomycin groups. The high-dose dapto-
mycin group presented the lowest inflammatory levels in CSF samples. Adjunctive treatment
with dexamethasone in this group modulated the inflammatory response, bringing down CSF
TNF-a levels.
Conclusion: CSF TNF-a levels were significantly lower in rabbits treated with daptomycin than
in rabbits treated with ceftriaxone. Daptomycin avoided the inflammatory peak afterof Experimental Infection, Infectious Diseases Department, Hospital Universitari de Bellvitge, Feixa
regat, Barcelona, Spain.
.com (M. Vivas).
.07.014
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436 M. Vivas et al.administration observed in ceftriaxone-treated rabbits. The use of daptomycin plus dexameth-
asone achieved a significantly larger reduction in CSF TNF-a levels.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Inflammation has been related to neuronal damage and
sequelae in patients with bacterial meningitis. Inflamma-
tion generated during antibiotic therapy may be dependent
on the antibiotic’s mechanism of action. Finding a therapy
without a significant host inflammatory cascade would be
particularly useful.
Certain bactericidal antibiotics that inhibit the synthesis
of the cell wall, such as b-lactams, cause bacterial lysis and
the release of proinflammatory bacterial products, leading
to an increased inflammatory response.1
Tumor necrosis factor alpha (TNF-a) is an important
early proinflammatory cytokine associated with
inflammation-related complications of bacterial meningi-
tis; patients with bacterial meningitis present increased
cerebrospinal fluid (CSF) TNF-a levels early in the course of
the disease.2 An early study by Saukkonen et al3 deter-
mined the role of cytokines in the CNS, including TNF-a,
using a rabbit model of meningeal inflammation. The re-
sults suggested that cytokines have multiple inflammatory
activities in the CNS and contribute to tissue damage.3
Several reports in an infant rat model by Barichello
et al4,5 evaluated the levels of TNF-a in the hippocampus
and prefrontal cortex, showing that the cytokine was pro-
duced mainly in the first 6e24 hours of the immune
response. TNF-a played an important role in the patho-
physiology and might be related to brain damage in the first
hours of pneumococcal meningitis.4,5
Daptomycin is a nonbacteriolytic antibiotic with
elevated bactericidal activity against a wide range of gram-
positive pathogens and may have minimal effects on cyto-
kine production.6
In experimental models of meningitis comparing its
effectiveness with that of ceftriaxone therapy, daptomycin
has already demonstrated a highly bactericidal effect and
its ability to attenuate inflammation in the CSF without
causing cortical damage.7,8
The aim of this study was to measure the inflammatory
response in terms of the release of TNF-a in the CSF,
comparing bacteriolytic and nonbacteriolytic antibiotic
therapy and adjunctive treatment with dexamethasone in
an experimental rabbit model of meningitis.Methods
Bacterial strain
A HUB 2349 penicillin- and cephalosporin-resistant strain of
Streptococcus pneumoniae belonging to serotype 23F and
isolated from a patient with meningitis was used. Minimuminhibitory concentration (MIC) and minimum biocidal con-
centration (MBC; mg/L) were as follows: penicillin 4/4;
ceftriaxone 2/4; vancomycin 0.25/0.25; and daptomycin
0.09/0.18.Meningitis model
The experimental protocol was in keeping with Spanish
legislation on animal experimentation and was approved by
the Ethics Committee for Animal Experiments at the Uni-
versity of Barcelona, Barcelona, Spain. The rabbit model of
meningitis described originally by Dacey and Sande9 was
used, with slight modifications. Young female New Zealand
white rabbits were anesthetized intramuscularly with
35 mg/kg of ketamine (Ketolar; Parke-Davs, Prat de Ll.,
Spain) and 5 mg/kg of xylazine (Rompum; Bayer AG, Lev-
erkusen, Germany). Meningitis was induced using an intra-
cisternal injection of 250 mL of a saline suspension
containing 106 colony forming units/mL of inoculum, and
therapy was started 18 hours postinoculation. Rabbits were
anesthetized using urethane (Sigma Chemical Company, St
Louis, MO, USA) at 1.75 g/kg subcutaneously and thiopental
sodium (Tiopental; B. Braun Medical S.A., Rubı´, Spain) at
5 mg/kg intravenously (iv). Animals were placed in the
stereotactic frame and a baseline CSF sample was taken
(0 hours). A dose of dexamethasone (Fortecortin; Merck,
Mollet del Valle´s, Barcelona, Spain) of 0.25 mg/24 h divided
every 12 hours was given intravenously. Ten minutes later,
antibiotic therapy was administered. CSF samples were
taken after 2 hours, 6 hours, 24 hours, and 26 hours of
therapy. Hydration was ensured throughout the experi-
ment. Mortality was assessed at 26 hours. Surviving animals
were euthanized using a lethal dose of thiopental sodium at
the end of each experiment.Therapeutic groups
Antibiotic iv therapy was then administered for 26 hours
using one of the following therapy schedules: ceftriaxone
(n Z 8 rabbits) at 100 mg/kg once daily, vancomycin at
15 mg/kg every 12 hours plus ceftriaxone (n Z 9 rabbits),
daptomycin (n Z 8 rabbits) at 15 mg/kg given once daily,
daptomycin (n Z 9 rabbits) 15 mg/kg given once daily plus
dexamethasone at 0.125 mg/kg every 12 hours, daptomycin
(n Z 9 rabbits) at 25 mg/kg given once daily, and dapto-
mycin (n Z 10 rabbits) 25 mg/kg given once daily plus
dexamethasone at 0.125 mg/kg every 12 hours. Untreated
controls received saline. The pharmacokinetics and phar-
macodynamics studies and the dosing regimens for antibi-
otics and dexamethasone have been previously
described.10,11
CSF TNF-a levels in pneumococcal meningitis 437Determination of TNF-a levels in CSF
TNF-a levels were determined by enzyme-linked immuno-
sorbent assay, according to the instructions of the manu-
facturer eBioscience, an Affymetrix company (Campus
Vienna Biocenter 2, Vienna, Austria).
Statistical analysis
All TNF-a counts are presented as picograms per milliliter
[mean  standard deviation (SD)]. Differences in TNF
counts between therapeutic groups were evaluated for
statistical significance using analysis of variance. An un-
paired Student t test with Bonferroni correction and anal-
ysis of variance was used to determine statistical
significance. For all tests, differences were considered to
be statistically significant when p < 0.05.
Results
The CSF TNF-a levels measured in pg/mL in rabbits infected
with a penicillin- and cephalosporin-resistant strain of S.
pneumoniae and treated with different antibiotic therapies
are presented in Table 1.
All the therapeutic groups showed good efficacy in terms
of the decrease of bacterial counts. At 6 hours of treat-
ment, CSF samples from all antibiotic groups were below 3
log from the initial inocula.
There were no significant differences in mortality at
26 hours in the therapeutic groups.
The control group did not present any significant varia-
tion in TNF-a levels during the experiment; at 24 hours
there was a slight decrease.
The ceftriaxone group had the highest levels of TNF-a
and presented an inflammatory peak after the administra-
tion of the antibiotic at 2 hours and 26 hours (2 hours after
the 2nd dose). Levels at 2 hours were significantly higher
than at baseline (pZ 0.02) and at 26 hours the differences
compared with 24 hours almost reached significance
(p Z 0.07).
The ceftriaxone plus vancomycin combination group
showed a moderate increase in inflammation after antibi-
otic administration, but lower than the ceftriaxone alone
group.Table 1 Tumor necrosis factor-alpha levels (pg/mL) in cerebro
with various antibiotic schedules (mg/L).
Therapy group
(dose in mg/kg/d)
CSF-
0 h 2 h
Control 1527  153.86 1360  496.34*
CRO 1263.46  519.85 2125.05  927.71**
CRO þ VAN 1448.06  571.04 1986.76  119.54
DAP 15 1313.88  469.44 1260.40  463.19*
DAP 25 1364.11  142.36 1304.48  942.26*
Data are expressed as mean  standard deviation.
* p 0.05 versus ceftriaxone group.
** p  0.05 intraceftriaxone group 2 hours versus 0 hours.
CRO Z ceftriaxone; DAP Z daptomycin; VAN Z vancomycin.However, daptomycin 15 mg/kg showed a constant
release of TNF-a levels without any significant increase in
inflammation at any point during treatment. Daptomycin
25 mg/kg showed a slight decrease after the second anti-
biotic administration, and was the antibiotic group with the
lowest proinflammatory levels at 26 hours. These CSF TNF-a
levels did not present an inflammatory peak after antibiotic
administration, and so no statistical differences were found
at either 2 hours or 26 hours.
CSF TNF-a levels were significantly higher in rabbits
treated with ceftriaxone than in rabbits treated with dap-
tomycin (both doses) at 2 hours and at 26 hours (pZ 0.03).
The TNF-a levels obtained from rabbits treated with dap-
tomycin at the doses of 15 mg/kg and 25 mg/kg alone and
with dexamethasone at 0.25 mg/kg are presented in
Figure 1.
Daptomycin 15 mg/kg plus dexamethasone reached the
same CSF inflammatory levels as daptomycin 15 alone; the
differences between the therapeutic groups were not
significant.
Concomitant administration of dexamethasone with
high-dose daptomycin increased the reduction in CSF TNF-a
levels and the difference after the first antibiotic admin-
istration was significantly lower than at baseline
(p Z 0.02). The inflammatory response measured in the
daptomycin 25 mg/kg plus dexamethasone group was
significantly lower than daptomycin 25 alone throughout
the treatment (p < 0.00).Discussion
Pneumococcal meningitis is firmly associated with a high
prevalence of brain injury and neurological sequelae due to
the synthesis and release of the main proinflammatory
mediators such as TNF-a into the central nervous system.
It has already been demonstrated in an experimental
infected rabbit model that TNF-a plays a fundamental role
in the pathogenesis of bacterial meningitis and its reduction
could notably improve therapeutic treatment.12
Another experimental study evaluated the inflammatory
response in rabbits treated with ceftriaxone, finding a
substantial increase in TNF-a levels 2 hours after the initi-
ation of the therapy using this bacteriolytic antibiotic in
comparison with untreated animals.13spinal fluid of rabbits with pneumococcal meningitis treated
TNF-a levels (pg/mL)
6 h 24 h 26 h
1481.18  1089.6 711.40  147.55 645  26.340*
1450.54  522.84 1390.08  729.50 2073.38  634.38
1634.49  1003.42 1951.90  787.68 1627.47  725.65
1519.89  653.54 1543.04  541.58 1302.13  108.83*
1557.84  1164.30 983.03  91.84 959.86  88.72*
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1262.95 ± 598.29 1682.73 ± 529.48 1755.57 ± 362.80 1000.00 ± 457.19 1131.58 ± 441.95
Data are expressed as mean ± standard deviation.
*p ≤ 0.05 versus daptomycin 25 group.
DAP = daptomycin; DEX = dexamethasone.
1544 ± 906.20 359 ± 209.14* 494.50 ± 463.68* 292.33 ± 174.88* 215.47 ± 131.54*
Figure 1. Cerebrospinal fluid tumor necrosis-alpha levels in rabbits treated with daptomycin at 15 mg/kg and 25 mg/kg and in
combination with dexamethasone at 0.25 mg/kg.
438 M. Vivas et al.Our results corroborated those by Mahmoud et al, who
found a similar response in terms of the release of TNF-a
when ceftriaxone is used.
For their part, animals treated with daptomycin pre-
sented with lower CSF TNF-a levels than those treated with
ceftriaxone alone or in combination with vancomycin. High-
dose daptomycin was the therapy group with the strongest
reduction in the inflammatory response after antibiotic
administration. Our results confirm and expand on earlier
experimental studies that compared the inflammatory
response of ceftriaxone-treated animals with daptomycin-
treated animals.7,8,14 Those data support our findings,
because it seems reasonable to attribute the effect to
daptomycin’s nonbacteriolytic mechanism. Nevertheless,
an extensive experimental study with Wistar rats by Bar-
ichello et al15 found no significant differences in cytokine
presence either in brain tissue or in CSF levels when cef-
triaxone and daptomycin therapies were compared. There
is no clear explanation for the differences between their
results and ours. Further research is needed to entirely
clarify the point. The CSF TNF-a levels with concomitant
administration of daptomycin and dexamethasone
remained constant in the case of low-dose daptomycin. In
high-dose daptomycin, dexamethasone modulated TNF-a
release, leading to a drastic decrease of proinflammatory
cytokine levels. The adjuvant therapy with dexamethasone
in combination with ceftriaxone has been extensively
studied. In an experimental rabbit model, Paris et al16
demonstrated a significant reduction in TNF-a inceftriaxone-treated animals when dexamethasone was
administered. Another clinical report demonstrated a
beneficial effect with the use of dexamethasone compared
with placebo alone.17 Even though additional research is
needed, our results may suggest that daptomycin could
present some advantages over b-lactam antibiotics with
regard to preventing inflammation and thus avoiding
neurological sequelae.
In conclusion, CSF TNF-a levels were significantly lower
in rabbits treated with daptomycin than in rabbits treated
with ceftriaxone, and did not present the peak after
administration found in ceftriaxone-treated rabbits. The
use of dexamethasone plus daptomycin resulted in a
significantly larger reduction of CSF TNF-a levels.Conflicts of interest
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